Prosecution Insights
Prosecution Insights
6 pending office actions • 5 clients • 6 examiners • 5 art units • 0 of 6 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| §102 only | 2 (33%) |
| §112 only | 1 (17%) |
| No statute on record | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GILL, RACHEL B | 1 | 65.5% | +28.0% |
| SHIBUYA, MARK LANCE | 1 | 32.3% | +24.9% |
| PARISI, JESSICA DANIELLE | 1 | 79.3% | +28.9% |
| BARRERA, IMMACULADA | 1 | 33.3% | +76.2% |
| GABEL, GAILENE | 1 | 75.6% | +44.9% |
| HAGHIGHATIAN, MINA | 1 | 45.8% | +39.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18317772 | METHODS OF TREATING METACHROMATIC LEUKODYSTROPHY | SHIBUYA, MARK LANCE | 37d overdue |
| 18315316 | FLOW CYTOMETRY ATTENUATED REPORTER EXPRESSION (FLARE) MULTIPLE REPORTER SYSTEM AND METHODS OF USE THEREOF | PARISI, JESSICA DANIELLE | 46d |
| 18627824 | MULTIVALENT INFLUENZA VACCINES | GILL, RACHEL B | — |
| 18250716 | ANTIBODIES AGAINST SARS-COV-2 AND USES THEREOF | BARRERA, IMMACULADA | — |
| 17919708 | METHODS AND SYSTEM FOR VALIDATING FLOW CYTOMETRY MEASUREMENTS | GABEL, GAILENE | — |
| 17262421 | Dry Powder Formulations for Messenger RNA | HAGHIGHATIAN, MINA | — |
| Client (Assignee) | Pending OAs |
|---|---|
| GENZYME CORPORATION | 2 |
| Sanofi | 1 |
| Kymab | 1 |
| Kiadis Pharma Intellectual Property B.V. | 1 |
| TRANSLATE BIO, INC. | 1 |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| 1684 | 1 |
| 1671 | 1 |
| 1678 | 1 |
| 1616 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18627824 | MULTIVALENT INFLUENZA VACCINES | Sanofi Pasteur Inc. | GILL, RACHEL B | §102 | Non-Final OA | — | Pending | Apr 05, 2024 | |
| 18317772 | METHODS OF TREATING METACHROMATIC LEUKODYSTROPHY | Genzyme Corporation | SHIBUYA, MARK LANCE | 1631 | Other | Non-Final OA | 37d overdue | Pending | May 15, 2023 |
| 18315316 | FLOW CYTOMETRY ATTENUATED REPORTER EXPRESSION (FLARE) MULTIPLE REPORTER SYSTEM AND METHODS OF USE THEREOF | Genzyme Corporation | PARISI, JESSICA DANIELLE | 1684 | §103 | Non-Final OA | 46d | Pending | May 10, 2023 |
| 18250716 | ANTIBODIES AGAINST SARS-COV-2 AND USES THEREOF | Kymab Limited | BARRERA, IMMACULADA | 1671 | §102 | Non-Final OA | — | Pending | Apr 26, 2023 |
| 17919708 | METHODS AND SYSTEM FOR VALIDATING FLOW CYTOMETRY MEASUREMENTS | Kiadis Pharma Intellectual Property B.V. | GABEL, GAILENE | 1678 | §112 | Non-Final OA | — | Pending | Oct 18, 2022 |
| 17262421 | Dry Powder Formulations for Messenger RNA | Translate Bio, Inc. | HAGHIGHATIAN, MINA | 1616 | Other | Non-Final OA | — | Pending | Jan 22, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial